Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Zimmer Biomet Holdings Inc (NYSE: ZBH) was $104.42 for the day, down -1.22% from the previous closing price of $105.71. In other words, the price has decreased by -$1.22 from its previous closing price. On the day, 1.2 million shares were traded. ZBH stock price reached its highest trading level at $105.4625 during the session, while it also had its lowest trading level at $104.13.
Ratios:
Our analysis of ZBH’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 37.14 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.70. For the most recent quarter (mrq), Quick Ratio is recorded 0.96 and its Current Ratio is at 1.87. In the meantime, Its Debt-to-Equity ratio is 0.60 whereas as Long-Term Debt/Eq ratio is at 0.54.
On December 17, 2024, JP Morgan Upgraded its rating to Overweight which previously was Neutral and also upped its target price recommendation from $125 to $128.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Aug 18 ’25 when Winkler Lori sold 1,500 shares for $102.49 per share. The transaction valued at 153,735 led to the insider holds 8,333 shares of the business.
Bezjak Mark bought 7,500 shares of ZBH for $766,708 on Aug 13 ’25. On Jun 13 ’25, another insider, Yi Sang, who serves as the Group President, Asia Pacific of the company, sold 800 shares for $92.51 each. As a result, the insider received 74,011 and left with 19,624 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBH now has a Market Capitalization of 20685182976 and an Enterprise Value of 27859083264. As of this moment, Zimmer’s Price-to-Earnings (P/E) ratio for their current fiscal year is 25.43, and their Forward P/E ratio for the next fiscal year is 12.19. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.95. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.64 while its Price-to-Book (P/B) ratio in mrq is 1.65. Its current Enterprise Value per Revenue stands at 3.556 whereas that against EBITDA is 10.762.
Stock Price History:
The Beta on a monthly basis for ZBH is 0.67, which has changed by -0.09239459 over the last 52 weeks, in comparison to a change of 0.13054323 over the same period for the S&P500. Over the past 52 weeks, ZBH has reached a high of $116.71, while it has fallen to a 52-week low of $89.22. The 50-Day Moving Average of the stock is 9.61%, while the 200-Day Moving Average is calculated to be 2.16%.
Shares Statistics:
ZBH traded an average of 1.96M shares per day over the past three months and 1563330 shares per day over the past ten days. A total of 197.90M shares are outstanding, with a floating share count of 197.82M. Insiders hold about 0.14% of the company’s shares, while institutions hold 98.48% stake in the company. Shares short for ZBH as of 1753920000 were 5926006 with a Short Ratio of 3.03, compared to 1751241600 on 8437875. Therefore, it implies a Short% of Shares Outstanding of 5926006 and a Short% of Float of 3.4299999999999997.
Dividends & Splits
With its trailing 12-month dividend rate of 0.96, ZBH has a forward annual dividend rate of 0.96. Against a Trailing Annual Dividend Yield of 0.009081449The stock’s 5-year Average Dividend Yield is 0.78. The current Payout Ratio is 21.66% for ZBH, which recently paid a dividend on 2025-06-26 with an ex-dividend date of 2025-06-26. Stock splits for the company last occurred on 2022-03-01 when the company split stock in a 103:100 ratio.
Earnings Estimates
The market rating of Zimmer Biomet Holdings Inc (ZBH) is currently shaped by the ongoing analysis conducted by 25.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $2.39, with high estimates of $2.49 and low estimates of $2.15.
Analysts are recommending an EPS of between $8.21 and $7.93 for the fiscal current year, implying an average EPS of $8.14. EPS for the following year is $8.55, with 27.0 analysts recommending between $9.01 and $8.31.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 23 analysts. It ranges from a high estimate of $2.03B to a low estimate of $1.98B. As of the current estimate, Zimmer Biomet Holdings Inc’s year-ago sales were $1.82BFor the next quarter, 23 analysts are estimating revenue of $2.23B. There is a high estimate of $2.25B for the next quarter, whereas the lowest estimate is $2.21B.
A total of 26 analysts have provided revenue estimates for ZBH’s current fiscal year. The highest revenue estimate was $8.25B, while the lowest revenue estimate was $8.11B, resulting in an average revenue estimate of $8.22B. In the same quarter a year ago, actual revenue was $7.68BBased on 25 analysts’ estimates, the company’s revenue will be $8.69B in the next fiscal year. The high estimate is $8.83B and the low estimate is $8.29B.
